About Index Trending news
Analyze
Top 50 Pricing
TxCell

TxCell

TxCell

TxCell develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases.

Elsewhere

Alexa global traffic share

Latest funding Show all
Venture capital
$21,361,708
Venture capital (Series C)
$16,075,360
Employees

Unknown size

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when TxCell makes some noise.